InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$499.74

2026-10-16

Market Cap

$126.7B

Volume

1.4M

52-Wk High

$560.25

52-Wk Low

$403.16

Trailing PE

28.9

P/S

10.03

Gross Margin

86.0%

Net Margin

34.9%

ROE

23%

ROIC

17%

Piotroski

5/9

Altman Z

12.9

1-Yr Return

+22.3%

5-Yr Return

+172.0%

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

SectorHealthcareIndustryBiotechnologyExchangeNASDAQMarket Cap$126.7BEmployees6,400 (SEC-filed)CEOReshma KewalramaniIPO1991-07-24CountryUS

50 Northern Avenue, Boston, MA 02210 · Tel 617 341 6100 · vrtx.com

INSIDERSTREET SCORE76 / 100Street mean $590.69 (13 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$42M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · VRTX +22.3% · S&P 500 +15.9% · spread +6.4pp

7 Years vs S&P 500 · VRTX +172.0% · S&P 500 +189.9% · spread -17.9pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE76of 100

Score Breakdown

Profitability	96/100
Growth	64/100
Momentum	80/100
Quality	86/100
Earnings Quality	75/100
Balance Sheet	97/100
Value	44/100
Risk (safety)	100/100
Overall	76.1/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
MRNA	30
REGN	68
ARGX	74
ONC	78
ALNY	68
ROIV	38
VRTX	76

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 86 in 23 Q1, latest 76 — -10 since. Fell in 3 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY76 / 100IS Score 76.1 / 100 · -9.6 from peak of 86

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBEARISHTechnical Score 34 / 100 · Power -33 · 7 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

These two disagree — business quality 76, price structure 34 out of 100, so the business reads better than the price does. We publish the disagreement rather than resolving it: they answer different questions, and the gap between them is information, not an error.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 76.1	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 77 → 73 → 77 → 76	the direction matters more than the level
Technical vote share back above 50%	now 18%	price structure no longer broken
Institutional holder count rises two quarters running	peak 1,754 → now 1,754	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)2 buys2026-09-04

Insider Buys (180d)0none disclosed

ETF Funds (30d)1639 up / 1391 downnet +248 funds

Institutions Added (13F)69managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 1,754 · latest 1,754 (+0 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	1,754	243.4M	$118.9B	95.9%
2026 Q1	1,685	235.1M	$103.5B	92.6%
2025 Q4	1,658	239.4M	$106.3B	94.3%
2025 Q3	1,509	232.2M	$88.9B	91.5%
2025 Q2	1,551	240.9M	$104.9B	94.9%
2025 Q1	1,603	240.1M	$112.2B	94.6%
2024 Q4	1,550	236.4M	$92.1B	93.1%
2024 Q3	1,535	235.0M	$106.1B	92.5%
2024 Q2	1,532	235.1M	$106.8B	92.6%
2024 Q1	1,483	235.6M	$93.4B	92.8%
2023 Q4	1,427	235.6M	$91.1B	92.8%
2023 Q3	1,264	236.1M	$77.8B	93.0%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Van Grunsven Jasper	EVP, CP and NPPO	2026-09-08	A-Award	8,682	—	8,682
Ambrose Kristen	SVP & Chief Accounting Officer	2026-08-28	A-Award	5,000	—	11,624
Sachs Bruce I	director	2026-08-27	GIFT	6,000	—	39,000
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	2026-07-21	A-Award	8,251	—	53,572
Sachdev Amit	EVP Chief Patient & Ext Af Off	2026-07-21	A-Award	8,251	—	66,512
Sachs Bruce I	director	2026-07-15	A-Award	100	—	15,772
Garber Alan M	director	2026-07-15	A-Award	32	—	65
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	2026-07-02	SELL	1,500	$0.79M	45,321

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	42	86,819	$41.8M	Counted
G — Gifts	1	6,000	—	None
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$41.8M42 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-08-27	Bruce I. Sachs	1,210	$0.7M
2026-07-02	Mckechnie Duncan	1,541	$0.8M
2026-07-02	Tatsis Ourania	1,500	$0.8M
2026-07-01	Liu Joy	828	$0.4M
Trailing 12 mo	58 filings	343,743	$157M

Filed	Form	Reporting person	% of class	Shares
2026-05-14	SCHEDULE 13G/A	Capital Research Global Investors	8.30%	21.1M sh
2026-05-14	SCHEDULE 13G/A	Capital World Investors	10.10%	25.7M sh
2026-04-30	SCHEDULE 13G	Vanguard Capital Management	7.49%	19.0M sh
2026-03-27	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-04	2026-10-09
David Taylor	House	SELL	$1,001 - $15,000	2026-08-26	2026-09-07
David J. Taylor	House	SELL	$1,001 - $15,000	2026-08-25	2026-09-07
Alan Armstrong	Senate	BUY	$1,001 - $15,000	2026-03-27	2026-07-21
Tommy Tuberville	Senate	SELL	$1,001 - $15,000	2024-05-03	2024-06-14
Tommy Tuberville	Senate	SELL	$1,001 - $15,000	2024-05-03	2024-06-13

House 12-Mo9 trades3 purchases

Senate 12-Mo1 trades1 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)1,685

13F Shares235M92.6% of shares out

New / Closed158 / 104positions, QoQ

Increased / Reduced678 / 594positions, QoQ

Put/Call (13F)0.93option positions

Free Float99.8%253M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Assenagon Asset Management S.A.	1.2M	$637M
Davenport & Co Llc	202,800	$106M
Montrusco Bolton Investments Inc.	149,888	$78M
Birch Hill Investment Advisors Llc	143,519	$75M
Fjarde Ap-Fonden /Fourth Swedish N	139,893	$73M
Vontobel Holding Ltd.	85,083	$44M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.2%	$4.2B
VTSAX	0.2%	$4.2B
VSMPX	0.2%	$4.2B
VTI	0.2%	$4.2B
VFFSX	0.2%	$3.5B
VFIAX	0.2%	$3.5B

13F Filers Holding VRTX — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session29.9%2026-10-15

20-Day Avg56.2%50-day 58.9%

TrendFalling20d vs 50d

By Market CenterQ: 29% · N: 45% · B: 46%latest session

Weekly Notional ($B)

Where VRTX Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	1.9M	30 sh
Ubsa Ubs Ats	1.8M	37 sh
Sgmt Sigma X2	1.1M	29 sh
Mlix Instinct X	0.9M	42 sh
Ebxl Level Ats	0.8M	19 sh
Mspl Ms Pool (Ats-4)	0.6M	66 sh

Where a dollar of Vertex Pharmaceuticals Incorporated revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
UNITED STATES	$7.5B	46%
Non-US	$5.4B	33%
Europe	$3.5B	21%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

VRTX (live moat model)Peer median: MRNA · REGN · ARGX · ONC · ALNY

Component scores from the live moat model. Peer median illustrative.

Moat score 56/100 — Narrow; primary source Network Effects.

3.8 · Employees (SEC filings)

Officer	Title
Reshma Kewalramani FASN	Chief Executive Officer, President & Director
Charles F. Wagner Jr.	Executive Vice President, Chief Operating Officer & Chief Financial Officer
Mark Bunnage D.Phil	Executive Vice President & Chief Scientific Officer
Carmen Bozic	Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)3 of 6recent quarters

Avg Surprise+1.6%

Next Report2026-11-02

Income Quality0.97OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+22.1%	+17.9%	+10.5%	+11.7%	+9.6%
Gross profit	+22.0%	+17.7%	+9.6%	+10.3%	+8.2%
Operating income	-2.6%	+54.8%	-11.0%	-106.1%	-2144.1%
Net income	-13.6%	+41.8%	+9.0%	-114.8%	-838.1%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	7.6	8.9	9.9	11.0	12.1
Cost of revenue	0.9	1.1	1.3	1.5	1.8
Gross profit	6.7	7.9	8.6	9.5	10.3
R&D expense	3.1	2.7	3.2	3.6	3.8
SG&A expense	0.8	0.9	1.1	1.5	1.8
Operating income	2.8	4.3	3.8	-0.2	4.8
EBITDA	2.9	4.4	4.6	0.5	5.0
D&A	0.1	0.1	0.2	0.2	0.2
Pretax income	2.7	4.2	4.4	0.2	4.6
Income tax	0.4	0.9	0.8	0.8	0.7
Net income	2.3	3.3	3.6	-0.5	4.0
Diluted EPS ($)	9.01	12.82	13.89	-2.08	15.32
Diluted shares (M)	260	259	260	258	258

Operating CF$4B

CapEx$0B

Free cash flow$3B

SBC$0B

Buybacks$2B

Net cash change$1B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	10.5	10.4	4.6	5.1
ST investments	0.3	0.8	1.5	1.5
Receivables (net)	1.4	1.6	1.6	2.1
Total current assets	13.2	14.1	9.6	11.2
PP&E (net)	1.5	1.5	2.6	3.1
Goodwill + intangibles	1.7	1.9	1.9	1.5
Total assets	18.2	22.7	22.5	26.1
Accounts payable	0.3	0.4	0.4	0.5
Short-term debt	0.0	0.0	0.1	0.1
Deferred revenue	0.2	0.2	0.2	0.2
Total current liabilities	2.7	3.5	3.6	3.9
Long-term debt	0.0	0.0	0.0	1.8
Total liabilities	4.2	5.1	6.1	7.5
Shareholders' equity	13.9	17.6	16.4	18.7

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	3.3	3.6	(0.5)	4.0
D&A	0.1	0.2	0.2	0.2
Stock-based compensation	0.5	0.6	0.7	0.0
Working capital change	0.3	(0.3)	(0.5)	(1.2)
Operating cash flow	4.1	3.5	(0.5)	3.6
Capital expenditures	(0.2)	(0.3)	(0.3)	(0.4)
Investing cash flow	(0.3)	(3.1)	(3.8)	(0.9)
Buybacks	(0.2)	(0.7)	(1.6)	(2.0)
Dividends paid	0.0	0.0	0.0	0.0
Debt issuance / (repay)	(0.1)	(0.0)	(0.0)	(0.0)
Financing cash flow	(0.1)	(0.6)	(1.5)	(2.3)
Free cash flow	3.9	3.3	(0.8)	3.2

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	24.9%	27.7%	23.0%	-3.2%	22.5%	23%
ROA	18.6%	21.0%	17.7%	-2.4%	16.2%	16.1%
ROIC	67.4%	83.8%	44.2%	4.2%	22.8%	17.3%
Gross margin	88.1%	87.9%	87.2%	86.1%	85.0%	86.0%
Operating margin	36.7%	48.2%	38.8%	-2.1%	39.4%	38.6%
Net margin	30.9%	37.2%	36.7%	-4.9%	32.7%	34.9%
EBITDA margin	38.5%	49.7%	46.7%	4.4%	41.1%	43.6%
FCF margin	31.8%	44.0%	33.8%	-8.9%	26.5%	—
VALUATION
P/E	24.10	22.63	29.33	-195.86	29.37	28.9
P/B	5.59	5.40	6.04	6.39	6.22	6.3
P/S	7.45	8.42	10.76	9.52	9.64	10.03
P/FCF	23.43	19.15	31.81	-107.26	36.35	33.4
EV/EBITDA	17.10	14.72	20.79	207.34	23.31	22.3
EV/Revenue	6.59	7.31	9.70	9.13	9.42	9.7
Earnings yield	4.1%	4.4%	3.4%	-0.5%	3.4%	3.47%
FCF yield	4.3%	5.2%	3.1%	-0.9%	2.8%	3.00%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	4.46	4.83	3.99	2.69	2.90	3.19
Quick ratio	4.30	4.66	3.78	2.35	2.46	2.74
Debt / equity	0.10	0.06	0.05	0.11	0.21	0.10
Debt / assets	7.2%	5.0%	3.6%	7.8%	14.9%	7.2%
Net debt / EBITDA	-2.25	-2.23	-2.26	-9.00	-0.56	-0.76
Interest coverage	45.39	78.23	100.32	9.12	350.11	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.60	0.57	0.48	0.49	0.49	0.46
Receivables turnover	7.49	6.93	6.57	6.94	6.57	5.9
DSO (days)	49	53	56	53	56	62
DPO (days)	71	84	97	93	97	89
Cash conversion cycle	106	106	132	192	278	338
GROWTH (YoY)
Revenue growth	22.1%	17.9%	10.5%	11.6%	9.3%	—
Net income growth	-13.6%	41.8%	9.0%	-114.8%	838.1%	—
EPS growth	-11.6%	40.0%	8.7%	-114.8%	850.8%	—
FCF growth	-19.5%	63.0%	-15.0%	-129.3%	426.6%	—
PER SHARE ($)
EPS (diluted, TTM)	9.11	12.76	13.87	-2.06	15.44	17.35
Book value / share	39.30	53.45	67.38	62.99	72.88	79.75
Revenue / share	29.47	34.31	37.83	42.29	47.01	49.72
FCF / share	9.37	15.08	12.79	-3.75	12.47	14.95
Cash / share	29.28	41.41	43.00	23.48	25.81	30.93
SHAREHOLDER RETURN & SCORES
Buyback yield	2.6%	0.2%	0.6%	1.5%	2.0%	1.76%
Altman Z-Score	12.41	13.11	14.63	11.73	11.43	12.9
Piotroski F-Score	8	7	3	4	7	5/9
Beneish M-Score	-2.32	-2.34	-2.09	-2.25	-2.18	-2.37

Model	Score	Zone	Note
Piotroski F-Score	5 / 9	Middling
Altman Z-Score	12.9	Safe (>2.99)	Safe
Income quality	0.97	Accrual-heavy	OCF ÷ net income
Beneish M-Score	-2.37	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.84
Interest burden	1.00
Operating margin	41.8%
Asset turnover	0.49×
Financial leverage	1.38×
= ROE	24%

Growth Quality (live)	Value
Revenue stability	0.99
Earnings stability	0.09
Earnings persistence	0.50
Revenue CAGR 3y	9.9%
EPS CAGR 3y	10.1%
FCF CAGR 3y	-0.7%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield1.76%

Dividend Yield0.00%none paid

Total Shareholder Return1.66%cash yield

SBC / Revenue5.5%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
MRNA	$87.0B	-27.3	-39%	—	-27.2%	2/9	+758.6%
REGN	$81.4B	18.9	14%	30.2%	+9.3%	7/9	+39.1%
ARGX	$51.5B	29.6	47%	29.8%	+242.1%	5/9	-2.2%
ONC	$39.4B	25.6	15%	13.9%	+34.3%	8/9	+16.0%
ALNY	$31.0B	38.0	101%	12.7%	+95.1%	6/9	—
ROIV	$24.2B	-88.2	-6%	—	-67.6%	1/9	—
INCY	$22.9B	13.9	31%	35.0%	+26.9%	8/9	—
UTHR	$22.9B	17.6	19%	42.5%	+2.5%	6/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

56 Analysts

Str Sell (0)Sell (1)Hold (7)Buy (48)Str Buy (0)

Mean Target (qtr)$590.6913 targets

Target vs. Price+18.2%last-quarter mean

Next Report2026-11-02street $4.76

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$13.25B	$13.42B / $13.18B	$18.68	$19.20 / $17.51	11
FY2027	$14.66B	$16.16B / $13.86B	$21.05	$23.54 / $18.56	12
FY2028	$16.47B	$17.57B / $15.09B	$25.16	$28.40 / $21.83	6

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$618.00	+23.7%	4
Last Quarter	$590.69	+18.2%	13
Last Year	$548.14	+9.7%	50
All Time	$467.60	-6.4%	110

Rolling mean of published targets vs. last close $499.74. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

A-

DCF

4/5

ROE

5/5

ROA

5/5

Debt/Eq

3/5

P/E

2/5

P/B

1/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

VRTX +22.3% vs S&P 500 +15.9% — spread +6.4pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$510.16	-10.42	-2.04%	Below
SMA 50	$522.54	-22.80	-4.36%	Below
SMA 200	$475.90	+23.84	+5.01%	Above
EMA 9	$503.21	-3.47	-0.69%	Below
EMA 21	$508.93	-9.19	-1.81%	Below
EMA 50	$510.43	-10.69	-2.09%	Below
EMA 200	$481.89	+17.85	+3.70%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBEARISHPower Score -337 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%33

Momentum 25%20

Volume 20%56

Volatility 10%0

Patterns 15%50

This Week18% bullishof 11 price-based votes

4 Weeks Ago18%+0 pts since

12 Weeks Ago36%-18 pts since

ReadStabilizingweek-over-week trajectory

Price vs SMA 20$510.16

Price vs SMA 50$522.54

Price vs SMA 200$475.90

EMA 9/21 Cross503.2/508.9

SMA 50/200Golden

ADX DirectionADX 21

Supertrend$533

Parabolic SAR$485

SMA Slope-0.430

RSI43.8

Stochastic K/D40/30

StochRSI K/D58/42

Williams %R-66

CCI-63

TSI vs Signal-14.3

CMO-12.4

ROC-0.99%

OBV SignalDistrib

Chaikin MF-0.170

MFI48

Force Index1M

Elder Ray Bull3.28

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 30

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$511.21 / $515.22 / $521.68	S1 / S2	$504.75 / $500.74
Bollinger (20,2)	$488.70 – $531.63	Squeeze	Off
52-wk range	$403.16 – $560.25	Off 52-wk high	-10.8%
ATR (14)	$13.24 (2.6%)	Historical vol	25.6%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+3.1%Jan70%

-1.2%Feb45%

+2.8%Mar52%

+4.8%Apr70%

+3.8%May55%

+4.1%Jun55%

+1.2%Jul60%

-0.6%Aug55%

-0.3%Sep30%

-1.4%Oct50%

-1.5%Nov65%

+2.9%Dec60%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	VRTX	S&P 500
Weekly volatility (σ, 1y)	2.95%	1.83%
Best / worst week (1y)	+8.4% / -7.6%	—
Max drawdown (5y, monthly)	-36.8%	—
1-week VaR (95%)	-4.2%	—
Beta (5y)	0.32	1.00

VRTX EQUITY WEATHER (LIVE)RAINY · -16

Trend-27

Momentum-14

Volume+36

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 347 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall-16.5+21.1 vs industry

Trend-27.2+12.3 vs industry

Momentum-14.0+34.5 vs industry

Volume+36.1+74.9 vs industry

Reading	VRTX	Biotechnology n=1,668	Healthcare n=5,272	All US symbols n=70,435
Overall	-16.5	-37.6	-24.0	-20.5
Trend	-27.2	-39.5	-25.6	-21.3
Momentum	-14.0	-48.5	-28.5	-15.8
Volume	+36.1	-38.8	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Reshma Kewalramani CEO and President	$21.1M	90% equity+incentive
Stuart A. Arbuckle Former EVP & Chief Operat	$10.0M	93% equity+incentive
Charles F. Wagner, Jr. EVP & Chief Operating	$8.2M	88% equity+incentive
Nia Tatsis EVP & Chief Regulatory and Qualit	$7.0M	89% equity+incentive
Amit Sachdev EVP & Chief Patient and Externa	$6.8M	89% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	53
Social	48
Governance	56
Composite ESG	52

Composite ESG Trend

Filed	8-K contents	Items
2026-09-01	Officer/Director Change	5.02
2026-08-03	Earnings Release; Exhibits	2.02,9.01
2026-07-07	Material Agreement; Regulation FD; Other Events; Exhibits	1.01,7.01,8.01,9.01
2026-05-13	Officer/Director Change; Shareholder Vote	5.02,5.07
2026-05-04	Earnings Release; Exhibits	2.02,9.01
2026-04-29	Officer/Director Change	5.02
2026-03-31	Other Events	8.01
2026-02-12	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-29 to 2026-08-03
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	113 rows · 1998 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-06-18 to 2026-09-08
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2026-03-27 to 2026-05-14
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Vertex Pharmaceuticals Incorporated (VRTX)

Institutions holding — 12 quarters

Vertex Pharmaceuticals Incorporated (VRTX)

Monthly Net Insider Flow (000 shares)

Signal Summary

Vertex Pharmaceuticals Incorporated (VRTX)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding VRTX — quarterly

Institutional Put/Call — quarterly

Vertex Pharmaceuticals Incorporated (VRTX)

Where VRTX Trades in the Dark

Vertex Pharmaceuticals Incorporated (VRTX)

3.8 · Employees (SEC filings)

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX)

Balance Sheet — Full

Cash Flow Statement — Full

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX)

Street Price Target — Trajectory

Third-Party Composite Rating

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX)

Family Scores (site weights)

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX)